Literature DB >> 14514738

X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study.

Jean Philippe Jais1, Bertrand Knebelmann, Iannis Giatras, Mario De Marchi, Gianfranco Rizzoni, Alessandra Renieri, Manfred Weber, Oliver Gross, Kai-Olaf Netzer, Frances Flinter, Yves Pirson, Karin Dahan, Jörgen Wieslander, Ulf Persson, Karl Tryggvason, Paula Martin, Jens Michael Hertz, Cornelis Schröder, Marek Sanak, Maria Fernanda Carvalho, Juan Saus, Corinne Antignac, Hubert Smeets, Marie Claire Gubler.   

Abstract

Alport syndrome (AS) is a type IV collagen hereditary disease characterized by progressive hematuric nephritis, hearing loss, and ocular changes. Mutations in the COL4A5 collagen gene are responsible for the more common X-linked dominant form of the disease characterized by much less severe disease in girls and women. A "European Community Alport Syndrome Concerted Action" (ECASCA) group was established to delineate the Alport syndrome phenotype in each gender and to determine genotype-phenotype correlations in a large number of families. Data concerning 329 families, 250 of them with an X-linked transmission, were collected. Characteristics of heterozygous girls and women belonging to the 195 families with proven COL4A5 mutation are compared with those of hemizygous boys and men. Hematuria was observed in 95% of carriers and consistently absent in the others. Proteinuria, hearing loss, and ocular defects developed in 75%, 28%, and 15%, respectively. The probability of developing end-stage renal disease or deafness before the age of 40 yr was 12% and 10%, respectively, in girls and women versus 90 and 80%, respectively, in boys and men. The risk of progression to end-stage renal disease appears to increase after the age of 60 yr in women. Because of the absence of genotype-phenotype correlation and the large intrafamilial phenotypic heterogeneity, early prognosis of the disease in X-linked Alport syndrome carriers remains moot. Risk factors for developing renal failure have been identified: the occurrence and progressive increase in proteinuria, and the development of a hearing defect.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514738     DOI: 10.1097/01.asn.0000090034.71205.74

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  140 in total

1.  Alport syndrome: About time--treating children with Alport syndrome.

Authors:  Judy Savige
Journal:  Nat Rev Nephrol       Date:  2012-05-29       Impact factor: 28.314

2.  Identification of the NC1 domain of {alpha}3 chain as critical for {alpha}3{alpha}4{alpha}5 type IV collagen network assembly.

Authors:  Valerie LeBleu; Malin Sund; Hikaru Sugimoto; Gabriel Birrane; Keizo Kanasaki; Elizabeth Finan; Caroline A Miller; Vincent H Gattone; Heather McLaughlin; Charles F Shield; Raghu Kalluri
Journal:  J Biol Chem       Date:  2010-09-16       Impact factor: 5.157

Review 3.  Living donor kidney transplantation in patients with hereditary nephropathies.

Authors:  Patrick Niaudet
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

Review 4.  The collagenopathies: review of clinical phenotypes and molecular correlations.

Authors:  Rebekah Jobling; Rohan D'Souza; Naomi Baker; Irene Lara-Corrales; Roberto Mendoza-Londono; Lucie Dupuis; Ravi Savarirayan; L Ala-Kokko; Peter Kannu
Journal:  Curr Rheumatol Rep       Date:  2014-01       Impact factor: 4.592

5.  The interface of genetics with pathology in alport nephritis.

Authors:  Helen Liapis; Sanjay Jain
Journal:  J Am Soc Nephrol       Date:  2013-09-26       Impact factor: 10.121

Review 6.  Ocular features in Alport syndrome: pathogenesis and clinical significance.

Authors:  Judy Savige; Shivanand Sheth; Anita Leys; Anjali Nicholson; Heather G Mack; Deb Colville
Journal:  Clin J Am Soc Nephrol       Date:  2015-02-03       Impact factor: 8.237

7.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

8.  Clinical and genetic features in autosomal recessive and X-linked Alport syndrome.

Authors:  Yanyan Wang; Vanessa Sivakumar; Mardhiah Mohammad; Deb Colville; Helen Storey; Frances Flinter; Hayat Dagher; Judy Savige
Journal:  Pediatr Nephrol       Date:  2013-11-02       Impact factor: 3.714

9.  Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure.

Authors:  Rachel Tan; Deb Colville; Yan Yan Wang; Lin Rigby; Judy Savige
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

10.  The use of ocular abnormalities to diagnose X-linked Alport syndrome in children.

Authors:  Ke Wei Zhang; Deb Colville; Rachel Tan; Colin Jones; Stephen I Alexander; Jeffrey Fletcher; Judy Savige
Journal:  Pediatr Nephrol       Date:  2008-03-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.